Antihypertensive Treatment

Chesley's Hypertensive Disorders in Pregnancy

Volumn , Issue , 2009, Pages 369-387

  Umans, Jason G ^a   Abalos, Edgardo J ^b   Lindheimer, Marshall D ^c  

^a GEORGETOWN UNIVERSITY   (United States)

^b Centro Rosario de Estudio Perinatales   (Argentina)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870333669     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374213-1.00020-3     Document Type: Chapter

References (137)

1. Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.(also reprinted as NIH publication 04-5230 and available at http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.htm).
2. H.R. Black and J.Y. Yi (1996) A new classification scheme for hypertension based on relative and absolute risk with implications for treatment and reimbursement. Hypertension 28 719-724.
3. L. Hansson, A. Zanchetti, S.G. Carruthers, et al., HOT Study Group (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 1755-1762.
4. B.M. Sibai, T.N. Abdella and G.D. Anderson (1983) Pregnancy outcome in 211 patients with mild chronic hypertension. Obstet Gynecol 61 571-576.
5. A.C. Guyton (1991) Blood pressure control – special role of the kidneys and body fluids. Science 252 1813-1816.
6. E.J. Lewis, L.G. Hunsicker, R.P. Bain and R.D. Rohde (for the Collaborative Study Group) (1993) The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Eng J Med 329 1456-1462.
7. B.M. Brenner, M.E. Cooper, D. de Zeeuw, et al., RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 345 861-869.
8. I. Giatras, J. Lau and A.S. Levey (for the Angiotensin Converting Enzyme Inhibition and Progresssive Renal Insufficiency Study Group) (1997) Effect of angiotensin converting enzyme inhibition on the progression of nondiabetic renal disease; a meta-analysis of randomized trials. Ann Intern Med 127 337-345.
9. S. Yusuf, R. Peto, J. Lewis, et al. (1985) Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 27 335-371.
10. M.A. Pfeffer, E. Braunwald and L.A. Moye (for the SAVE Investigators) (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trials. N Eng J Med 327 669-677.
11. B. Pitt, W. Remme, F. Zannad, et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med. 348 1309-1321.
12. R. Garg and S. Yusuf (for the Collaborative Group on ACE Inhibitor Trials) (1995) Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 1450-1456.
13. B. Pitt, R. Segal and F.A. Martinez (for the ELITE Study Investigators) (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 375-380.
14. B. Pitt, F. Zannad, W.J. Remme, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Eng J Med 341 709-717.
15. SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 3255-3264.
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 2981-2997.
17. B.J. Materson, D.J. Reda and W.C. Cushman (for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents) (1993) Single drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. N Eng J Med 328 914-921.
18. M.H. Weinberger, J.E. Stegner and N.S. Fineberg (1993) A comparison of two tests for the assessment of blood pressure responses to sodium. Am J Hypertens 6 179-184.
19. W. Kiowski, F.R. Buhler, M.O. Fadayomi, et al. (1985) Age, race, blood pressure and renin; predictors for antihypertensive treatment with calcium antagonists. Am J Cardiol 56 81H-85H.
20. R.B. Merkatz, R. Temple, S. Subel, et al., The Working Group on Women in Clinical Trials (1993) Women in clinical trials of new drugs. A change in Food and Drug Administration policy. N Eng J Med 329 292-296.
21. http://www.fda.gov/cder/regulatory/pregnancy_labeling/default.htm.
22. Veterans Administration Cooperative Study Group on Antihypertensive Agents (1967) Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202 1028-1034.
23. C.W.G. Redman, L.J. Beilin, J. Bonnar and M.K. Ounsted (1976) Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 2 753-756.
24. B.M. Sibai, W.C. Mabie, F. Shamsa, et al. (1990) A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 162 960-967.
25. H.M. Leather, D.M. Humphreys, P.B. Paker and M.A. Chadd (1968) A controlled trial of hypotensive agents in hypertension in pregnancy. Lancet 2 488-490.
26. I. Fidler, V. Smith, P. Fayers and M. de Swiet (1983) Randomized controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. Br Med J 286 1927-1930.
27. E.D.M. Gallery, M.R. Ross and A.Z. Gyory (1985) Antihypertensive treatment in pregnancy: Analysis of different responses to oxprenolol and methyldopa. Br Med J 291 563-566.
28. J.S. Horvath, A. Phippard, A. Korda, et al. (1985) Clonidine hydrochloride – a safe and effective antihypertensive agent in pregnancy. Obstet Gynecol 66 634-638.
29. P.F. Plouin, G. Breart, F. Maillard, et al. (1988) Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: A randomized controlled trial. Br J Obstet Gynaecol 95 868-876.
30. J. Cockburn, V.A. Moar, M. Ounsted and C.W. Redman (1982) Final report of study on hypertension during pregnancy: The effects of specific treatment on the growth and development of the children. Lancet 1 647-649.
31. H.F. Schobel, T. Fischer, K. Heuszer, et al. (1996) Preeclampsia-a state of sympathetic overactivity. N Eng J Med 335 1480-1485.
32. C.W. Redman, L.J. Beilin and J. Bonnar (1977) Treatment of hypertension in pregnancy with methyldopa: Blood pressure control and side effects. Br J Obstet Gynaecol 84 419-426.
33. S. Montan, C. Anandakumar, S. Arulkumaran, et al. (1993) Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol 168 152-156.
34. L.M. Mutch, V.A. Moar, M.K. Ounsted and C.W. Redman (1977) Hypertension during pregnancy, with and without specific hypotensive treatment. 1. Perinatal factors and neonatal morbidity. Early Hum Dev 1 47-57.
35. L.M. Mutch, V.A. Moar, M.K. Ounsted and C.W. Redman (1977) Hypertension during pregnancy, with and without specific hypotensive treatment. II. The growth and development of the infant in the first year of life. Early Hum Dev 1 59-67.
36. H.I. Huisjes, M. Hadders-Algra and B.C. Touwen (1986) Is clonidine a behavioural teratogen in the human? Early Hum Dev 14 43-48.
37. B. Dahlöf, R.B. Devereux, S.E. Kjeldsen, et al., LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 995-1003.
38. E.L. Schiffrin (1998) Vascular remodeling and endothelial function in hypertensive patients: Effects of antihypertensive therapy. Scand Cardiovasc J 47 15-21S.
39. P.C. Rubin, L. Butters, D.M. Clark, et al. (1983) Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet 1 431-434.
40. K. Wichman, G. Ryden and B.E. Karlberg (1984) A placebo controlled trial of metoprolol in the treatment of hypertension in pregnancy. Scand J Clin Lab Med Invest 44(Suppl 169), 90-94.
41. S. Hogstedt, S. Lindeberg, O. Axelsson, et al. (1985) A prospective controlled trial of metoprololhydralazine treatment in hypertension during pregnancy. Acta Obstet Gynecol Scand 64 505-510.
42. L. Butters, S. Kennedy and P.C. Rubin (1990) Atenolol in essential hypertension during pregnancy. Br Med J 301 587-589.
43. P.F. Plouin, G. Breart, J. Llado, et al. (1990) A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. Br J Obstet Gynaecol 97 134-141.
44. D. Jannet, B. Carbonne, E. Sebban and J. Milliez (1994) Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: A randomized comparative trial. Obstet Gynecol 84 354-359.
45. E. Paran, G. Holzberg, M. Mazor, et al. (1995) Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. Int J Clin Pharmacol Ther 33 119-123.
46. B. Reynolds, L. Butters, J. Evans, et al. (1984) First year of life after the use of atenolol in pregnancy associated hypertension. Arch Dis Child 59 1061-1063.
47. G.Y. Lip, M. Beevers, D. Churchill, et al. (1997) Effect of atenolol on birthweight. Am J Cardiol 79 1436-1438.
48. C. Lydakis, G.Y.H. Lip, M. Beevers and D.G. Beevers (1999) Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 12 541-547.
49. H. Bayliss, D. Churchill, M. Beevers and D.G. Beevers (2002) Anti-hypertensive drugs in pregnancy and fetal growth: evidence for “pharmacological programming” in the first trimester? Hypertens Pregnancy 21 161-174.
50. S. Montan, I. Ingemarsson, K. Marsal and N.O. Sjoberg (1992) Randomised controlled trial of atenolol and pindolol in human pregnancy: Effects on fetal haemodynamics. Br Med J 304 946-949.
51. E.J. Waterman, L.A. Magee, K.I. Lim, A. Skoll, D. Rurak and P. von Dadelszen (2004) Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review. Hypertens Pregnancy 23 155-169.
52. W.C. Mabie, A.R. Gonzalez, B.M. Sibai and E. Amon (1987) A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 70 328-333.
53. C.A. Michael (1986) Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. Aust N Z J Obstet Gynaecol 26 26-29.
54. R.G. Ashe, J. Moodley, A.M. Richards and R.H. Philpott (1987) Comparison of labetalol and dihydralazine in hypertensive emergencies in pregnancy. S Afr Med J 71 354-356.
55. L.A. Magee, C. Cham, E.J. Waterman, A. Ohlsson and von Dadelszen (2003) Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 327 955.
56. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD001449.
57. C.J. Pickles, E.M. Symonds and F.B. Pipkin (1989) The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol 96 38-43.
58. C.W.G. Redman (1982) A controlled trial of the treatment of hypertension in pregnancy: Labetalol compared with methyldopa. A. Riley, E.M. Symonds (Eds) The Investigation and Management of Hypertension in Pregnancy Amsterdam: Excerpta Medica 111-122.
59. A.M. el-Qarmalawi, A.H. Morsy, A. al-Fadly, et al. (1995) Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet 49 125-130.
60. B.M. Sibai, A.R. Gonzalez, W.C. Mabie and M. Moretti (1987) A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol 70 323-327.
61. U.K. Munshi, A.K. Deorari and V.K. Paul (1992) Singh M: Effects of maternal labetalol on the newborn infant. Indian Pediatr 29 1507-1512.
62. T.R. Easterling, T.J. Benedetti, B.C. Schmucker and S.P. Millard (1990) Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet Gynecol 76 1061-1069.
63. P.M. Bosio, P.J. McKenna, R. Conroy and C. O’Herlihy (1999) Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol. 94 978-984.
64. T.R. Easterling, D. Brateng, B. Schmucker, Z. Brown and S.P. Millard (1999) Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol 93 725-733.
65. T.R. Easterling, D.B. Carr, D. Brateng, C. Diederichs and B. Schmucker (2001) Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 98 427-433.
66. D.T. Freier and N.W. Thompson (1993) Pheochromocytoma and pregnancy: The epitome of high risk. Surgery 114 1148-1152.
67. I.M. Wilson and I.M. Freis (1959) Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation 20 1028-1036.
68. J.C. Roos, P. Boer, H.A. Koomaans, et al. (1981) Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension. Eur J Clin Pharmacol 19 107-112.
69. W.M. Bennett, W.J. McDonald, E. Kuehnel, et al. (1977) Do diuretics have antihypertensive properties independent of natriuresis. Clin Pharmacol Ther 22 499-504.
70. R. Collins, S. Yusuf and R. Peto (1985) Overview of randomised trials of diuretics in pregnancy. Br Med J 290 17-23.
71. B.M. Sibai, R.A. Grossman and H.G. Grossman (1984) Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol 150 831-835.
72. E.D.M. Gallery, S.N. Hunyor and A.Z. Gyory (1979) Plasma volume contraction: A significant factor in both pregnancy-associated hypertension (preeclampsia) and chronic hypertension in pregnancy. Q J Med 192 593-602.
73. W. Visser and H.C.S. Wallenburg (1991) Central hemodynamic observations in untreated preeclamptic patients. Hypertension 17 1072-1077.
74. National High Blood Pressure Education Program Working Group report on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:S1–S22 (Also reprinted as NIH Publication No. 00-3029 and available at http://www.nhlbi.nih.gov/guidelines/archives/hbp_preg/index.htm).
75. L.R. Krusell, L.T. Jespersen, A. Schmitz, et al. (1987) Repetitive natriuresis and blood pressure. Longterm calcium entry blockade with isradipine. Hypertension 10 577-581.
76. R.M. Brouwer, P. Bolli, P. Erne, et al. (1985) Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. Cardiovasc Pharmacol 7 S88-S91.
77. C.D. Furberg, B.M. Psaty and J.V. Meyer (1995) Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 92 1326-1331.
78. A.V. Chobanian (1996) Calcium channel blockers. Lessons learned from MIDAS and other clinical trials. JAMA 276 829-830.
79. L.A. Magee, B. Schick, A.E. Donnenfeld, et al. (1996) The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study. Am J Obstet Gynecol 174 823-828.
80. C. Weber-Schoendorfer, D. Hannemann, R. Meister, et al. (2008) The safety of calcium channel blockers during pregnancy: A prospective, multicenter, observational study. Reprod Toxicol 26 24-30.
81. B.M. Sibai, J.R. Barton, S. Akl, et al. (1992) A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol 167 879-884.
82. A.A. Ismail, I. Medhat, T.A. Tawfic and A. Kholeif (1993) Evaluation of calcium-antagonist (Nifedipine) in the treatment of pre-eclampsia. Int J Gynaecol Obstet 40 39-43.
83. L.M. Hanff, A.G. Vulto, P.A. Bartels, D.W. Roofthooft, B.N. Bijvank, E.A. Steegers and W. Visser (2005) Intravenous use of the calcium-channel blocker nicardipine as second-line treatment in severe, early-onset pre-eclamptic patients. J Hypertens. 23 2319-2326.
84. D.H. Wide-Swensson, I. Ingemarsson, N.O. Lunell, et al. (1995) Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: A randomized placebo-controlled study. Am J Obstet Gynecol 173 872-878.
85. M.A. Belfort, J. Anthony, G.R. Saade and J.C. Allen Nimodipine Study Group (2003) A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Eng J Med 348 304-311.
86. M.A. Belfort, J. Anthony, A. Buccimazza and D.A. Davey (1990) Hemodynamic changes associated with intravenous infusion of the calcium antagonist verapamil in the treatment of severe gestational proteinuric hypertension. Obstet Gynecol 75 970-974.
87. E.D. Gallery and A.Z. Gyory (1997) Sublingual nifedipine in human pregnancy. Aust N Z J Med 27 538-542.
88. J. van Harten, K. Burggraaf, M. Danhof, et al. (1987) Negligible sublingual absorption of nifedipine. Lancet 2 1363-1365.
89. K. Fenakel, G. Fenakel, Z. Appelman, et al. (1991) Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 77 331-337.
90. S.J. Seabe, J. Moodley and P. Becker (1989) Nifedipine in acute hypertensive emergencies in pregnancy. S Afr Med J 76 248-250.
91. S. Martins-Costa, J.G. Ramos, E. Barros, et al. (1992) Randomized, controlled trial of hydralazine versus nifedipine in preeclamptic women with acute hypertension. Clin Exp Hypertens 11 25-44.
92. R. Jegasothy and S. Paranthaman (1996) Sublingual nifedipine compared with intravenous hydralazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice. J Obstet Gynaecol Res 22 21-24.
93. W. Visser and H.C. Wallenburg (1995) A comparison between the hemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe preeclampsia. J Hypertens 13 791-795.
94. C.W. Blea, J.M. Barnard, R.R. Magness, et al. (1997) Effect of nifedipine on fetal and maternal hemodynamics and blood gases in the pregnant ewe. Am J Obstet Gynecol 176 922-930.
95. G.D. Waisman, L.M. Mayorga, M.I. Camera, et al. (1988) Magnesium plus nifedipine: Potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol 159 308-309.
96. M. BenAmi, Y. Giladi and E. Shalev (1994) The combination of magnesium sulphate and nifedipine: A cause of neuromuscular blockade. Br J Obstet Gynaecol 101 262-263.
97. L. Magee, S. Miremadi, J. Li, et al. (2005) Therapy with both magnesium sulphate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with pre-eclampsia. Am J Obstet Gynecol 193 153-163.
98. Wallenburg HCS. Hemodynamics in hypertensive pregnancy. In: Rubin PC, ed. Hypertension in Pregnancy. New York: Elsevier; 1988:66-101 (second edition in press 1999 or 2000 ).
99. G.J. Vink, J. Moodley and R.H. Philpott (1980) Effect of dihydralazine on the fetus in the treatment of maternal hypertension. Obstet Gynecol 55 519-522.
100. E. Widerlov, I. Karlman and J. Storsater (1980) Hydralazine-induced neonatal thrombocytopenia. N Eng J Med 303 1235.
101. D.K.L. Dudley (1985) Minibolus diazoxide in the management of severe hypertension in pregnancy. Am J Obstet Gynecol 151 196-200.
102. B. Nuwayhid, C.R. Brinkman, B. Katchen, et al. (1975) Maternal and fetal hemodynamic effects of diazoxide. Obstet Gynecol 46 197-203.
103. A. Hennessy, C.E. Thornton, A. Makris, R.F. Ogle, D.J. Henderson-Smart, A.G. Gillin and A. Child (2007) A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial. Aust N Z J Obstet Gynaecol. 47 279-285.
104. B.M. Boulos, L.E. Davis and C.H. Almond (1971) Jackson RL: Placental transfer of diazoxide and its hazardous effect on the newborn. J Clin Pharmacol J New Drugs 11 206-210.
105. C.T. Shoemaker and M. Meyers (1984) Sodium nitroprusside for control of severe hypertensive disease of pregnancy: A case report and discussion of potential toxicity. Am J Obstet Gynecol 149 171-173.
106. N. Wasserstrum (1991) Nitroprusside in preeclampsia. Circulatory distress and paradoxical bradycardia. Hypertension 18 79-84.
107. J. Rosenthal (1993) Role of renal and extrarenal renin-angiotensin system in the mechanism of arterial hypertension and its sequelae. Steroids 58 566-572.
108. K. Takahama, T. Araki, J. Fuchikami, et al. (1996) Studies on the magnitude and the mechanism of cough potentiation by angiotensin-converting enzyme inhibitors in guinea pigs: Involvement of bradykinin in the potentiation. J Pharm Pharmacol 48 1027-1033.
109. M.K. Raizada and A.J. Ferreira (2007) ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50 112-119.
110. D.C. Merrill, M. Karoly, K. Chen, C.M. Ferrario and K.B. Brosnihan (2002) Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 18 239-245.
111. S. Ito, S. Arima, Y.L. Ren, et al. (1993) Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 91 2012-2019.
112. N. Chapman, J. Dobson, S. Wilson, B. Dahlöf, P.S. Sever, H. Wedel and N.R. Poulter Anglo-Scandinavian Cardiac Outcomes Trial Investigators (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 839-845.
113. P. August, F.B. Mueller, J.E. Sealey and T.G. Edersheim (1995) Role of renin-angiotensin system in blood pressure regulation in pregnancy. Lancet 345 896-897.
114. P.N. Baker, F.B. Pipkin and E.M. Symonds (1992) Comparative study of platelet angiotensin II binding and the angiotensin II sensitivity test as predictors of pregnancy-induced hypertension. Clin Sci (Colch) 83 89-95.
115. T.R. Easterling, D.B. Carr, C. Davis, C. Diederichs, D.A. Brateng and B. Schmucker (2000) Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol 96 956-961.
116. P.G. Pryde, A.B. Sedman, C.E. Nugent and M. Barr Jr. (1993) Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 3 1575-1582.
117. R. Serreau, D. Luton, M.A. Macher, A.L. Delezoide, C. Garel and E. Jacqz-Aigrain (2005) Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG 112 710-712.
118. W.O. Cooper, S. Hernandez-Diaz, P.G. Arbogast, et al. (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Eng J Med. 354 2443-2451.
119. G.G. Briggs, R.K. Freeman and S.J. Yaffe (2005) Drugs in Pregnancy: A Reference Guide to Fetal and Neonatal Risk. 7th ed Philadelphia: Lippincott Williams and Wilkins
120. H.C. Atkinson, E.J. Begg and B.A. Darlow (1988) Drugs in human milk: Clinical pharmacokinetic considerations. Clin Pharmacokinet 14 217-240.
121. R.L. Breitzka, T.L. Sandritter and F.K. Hatzopoulos (1997) Principles of drug transfer into breast milk and drug disposition in the nursing infant. J Hum Lact 13 155-158.
122. K.S. Beardmore, J.M. Morris and E.D. Gallery (2002) Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy 21 85-95.
123. R.G. Devlin and P.M. Fleiss (1981) Captopril in human blood and breast milk. J Clin Pharmacol. 21 110-113.
124. R. Collins and S. MacMahon (2001) Reliable assessment of the effects of treatment on mortality and major morbidity. I: Clinical trials. Lancet 357 373-380.
125. J. Stepheson and J. Imrie (1998) Why do we need randomized controlled trials to assess behavioural interventions. BMJ 316 611-613.
126. J. Villar and G. Carroli (1996) Methodological issues of randomized controlled trials for the evaluation of reproductive health interventions. Prev Med 25 365-375.
127. J. Villar, M.E. Mackey, G. Carroli and A. Donner (2001) Meta-analyses in systematic reviews of randomized controlled trials in perinatal medicine: comparison of fixed and random effect model. Statist Med 20 3635-3647.
128. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002252.
129. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD002863.
130. J.G. Umans and M.D. Lindheimer (2001) Antihypertensive therapy in pregnancy. Curr Hypertens Rep 3 392-399.
131. R.L. Ferrer, B.M. Sibai, C.D. Mulrow, et al. (2000) Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 96 849-860.
132. P. Von Dadelszen, M. Ornstein, S. Bull, A. Logan, G. Koren and L. Magee (2000) Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 355 87-92.
133. P. von Dadelszen and L.A. Magee (2002) Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can. 24 941-945.
134. Magee LA, von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M, et al. The Control of Hypertension In Pregnancy Study pilot trial. BJOG 2007; 114:770, e13–20.
135. M.A. Belfort, C. Tooke-Miller, J.C. Allen Jr., D. Dizon-Townson and M.A. Varner (2002) Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas. Hypertens Pregnancy 21 185-197.
136. L.A. Magee, M. Helewa, J.M. Moutquin and P. von Dadelszen Hypertension Guideline Committee (2008) Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. J Obstet Gynaecol Can 30 S1-S48.
137. D. Altman, G. Carroli, L. Duley, B. Farrell, J. Moodley, J. Neilson and D. Smith Magpie Trial Collaborative Group (2002) Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 359 1877-1890.